- Titulinis
- Dalykinė ir mokslinė literatūra
- Medicinos knygos
- Medicina, bendrieji dalykai
- Considering the Patient in Pediatric Drug Development

Klaus Rose
Considering the Patient in Pediatric Drug Development
Balsavo 0
ISBN: 9780128238882
Autorius : Klaus Rose
Leidimo metai: 2020
Leidėjas: Academic Press
Leidinio kalba: Anglų
Formatas: Minkšti viršeliai
Formatas: 9×6
Autorius : Klaus Rose
Leidimo metai: 2020
Leidėjas: Academic Press
Leidinio kalba: Anglų
Formatas: Minkšti viršeliai
Formatas: 9×6
Kaina:
Šių parametrų produkto neturime
Likutis pakankamas
Iš leidyklos gausime per 3-5 savaitės. Galimas vėlavimas
Turime sandėlyje. Pristatymas Lietuvoje 1-4 d.d.
Iš leidyklos gausime per 3-5 savaitės. Galimas vėlavimas
Pristatymo sąlygos
Aprašymas
<p><i>Considering the Patient in Pediatric Drug Development: How Good Intentions Turned into Harm</i> addresses a fundamental challenge in drug development and healthcare for young patients. In clinical trials and clinical practice, the term "children" is used ambiguously to confer physiological characteristics to a chronological age limit, which in reality does not exist. This book outlines why the United States (US) and European Union's (EU) regulatory authorities, pediatric academia, and the pharmaceutical industry demand, support and perform pediatric drug studies, along with the key flaws of this demand that blurs the different administrative and physiological meanings of the term "child."</p> <p>In addition, the book covers why most pediatric regulatory studies lack medical sense and many even harm young patients and the conflicts of interest behind pediatric drug studies. It includes relevant information about the maturation of the human body regarding absorption, distribution, metabolism and excretion of food and drugs as well as key differences between newborns, infants, older children and adolescents. </p>
Atsiliepimai (0)
Palikite atsiliepimą